These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 8892752

  • 21. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V, Muller P, Brozkova K, Vojtesek B.
    Biochem Biophys Res Commun; 2006 Dec 15; 351(2):499-506. PubMed ID: 17070499
    [Abstract] [Full Text] [Related]

  • 22. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
    Preuss U, Kreutzfeld R, Scheidtmann KH.
    Int J Cancer; 2000 Oct 15; 88(2):162-71. PubMed ID: 11004663
    [Abstract] [Full Text] [Related]

  • 23. Co-localization of endogenous and exogenous p53 proteins in nasopharyngeal carcinoma cells.
    Hwang JK, Lin CT.
    J Histochem Cytochem; 1997 Jul 15; 45(7):991-1003. PubMed ID: 9212825
    [Abstract] [Full Text] [Related]

  • 24. Novel DNA binding of p53 mutants and their role in transcriptional activation.
    Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB.
    Oncogene; 1993 Sep 15; 8(9):2555-9. PubMed ID: 8361764
    [Abstract] [Full Text] [Related]

  • 25. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Chen JY, Funk WD, Wright WE, Shay JW, Minna JD.
    Oncogene; 1993 Aug 15; 8(8):2159-66. PubMed ID: 8336941
    [Abstract] [Full Text] [Related]

  • 26. Regulation of mutant p53 temperature-sensitive DNA binding.
    Friedlander P, Legros Y, Soussi T, Prives C.
    J Biol Chem; 1996 Oct 11; 271(41):25468-78. PubMed ID: 8810317
    [Abstract] [Full Text] [Related]

  • 27. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein.
    Maiyar AC, Phu PT, Huang AJ, Firestone GL.
    Mol Endocrinol; 1997 Mar 11; 11(3):312-29. PubMed ID: 9058378
    [Abstract] [Full Text] [Related]

  • 28. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A, Resnick MA.
    Oncogene; 2001 Jun 07; 20(26):3409-19. PubMed ID: 11423991
    [Abstract] [Full Text] [Related]

  • 29. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
    Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P.
    Oncogene; 2001 Jun 14; 20(27):3533-40. PubMed ID: 11429700
    [Abstract] [Full Text] [Related]

  • 30. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
    Takimoto R, El-Deiry WS.
    Oncogene; 2000 Mar 30; 19(14):1735-43. PubMed ID: 10777207
    [Abstract] [Full Text] [Related]

  • 31. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
    Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, Wada K, Nishisaki H, Konda Y, Nagao M.
    Cancer Res; 1992 Aug 15; 52(16):4335-41. PubMed ID: 1322785
    [Abstract] [Full Text] [Related]

  • 32. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
    Miller CW, Chumakov A, Said J, Chen DL, Aslo A, Koeffler HP.
    Oncogene; 1993 Jul 15; 8(7):1815-24. PubMed ID: 8510927
    [Abstract] [Full Text] [Related]

  • 33. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC, Levine AJ.
    Cell Growth Differ; 1994 Jan 15; 5(1):61-71. PubMed ID: 8123594
    [Abstract] [Full Text] [Related]

  • 34. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
    Gagnebin J, Kovar H, Kajava AV, Estreicher A, Jug G, Monnier P, Iggo R.
    Oncogene; 1998 Feb 05; 16(5):685-90. PubMed ID: 9482117
    [Abstract] [Full Text] [Related]

  • 35. Specific DNA binding by different classes of human p53 mutants.
    Rolley N, Butcher S, Milner J.
    Oncogene; 1995 Aug 17; 11(4):763-70. PubMed ID: 7651740
    [Abstract] [Full Text] [Related]

  • 36. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
    Leiter LM, Chen J, Marathe T, Tanaka M, Dutta A.
    Oncogene; 1996 Jun 20; 12(12):2661-8. PubMed ID: 8700525
    [Abstract] [Full Text] [Related]

  • 37. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
    Kichina JV, Rauth S, Das Gupta TK, Gudkov AV.
    Oncogene; 2003 Jul 31; 22(31):4911-7. PubMed ID: 12894234
    [Abstract] [Full Text] [Related]

  • 38. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.
    Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R.
    Cancer Res; 1996 Feb 15; 56(4):765-71. PubMed ID: 8631011
    [Abstract] [Full Text] [Related]

  • 39. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
    Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S.
    Oncogene; 2002 Jan 10; 21(2):176-89. PubMed ID: 11803461
    [Abstract] [Full Text] [Related]

  • 40. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
    Gollahon LS, Shay JW.
    Oncogene; 1996 Feb 15; 12(4):715-25. PubMed ID: 8632893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.